Author
Imperial College LondonORCID 0009-0007-0339-514XUnclaimed ORCID profile · follow to get notified of new preprints
4 papers
Recent·Most cited
Carmen Ramírez-Moncayo, Restuadi Restuadi, Guanying Zhang…·Louise Fets
The paper uses multimodal imaging to show that lysosomes act as a reservoir for PARP inhibitors, leading to heterogeneous drug distribution and response in ovarian cancer.
Daniel Marks, Edwin García, Sunil Kumar…·Iain A. McNeish
This paper develops a CRISPR-engineered FRET biosensor to study PARP trapping dynamics in ovarian cancer cells and identifies reduced trapping in PARPi-resistant models.
Michael Gruet, Yitao Xu, Lijie An…·Hector C. Keun
This study identifies RAS/PI3K pathway mutations as a biomarker for sensitivity to PARP/NAMPT inhibitor combination therapy in epithelial ovarian cancer.
Sarah Spear, Olivia Le Saux, Hasan Mirza…·Iain A. McNeish
This study identifies HMOX1-expressing omental macrophages as a therapeutic target and biomarker for poor prognosis ovarian high-grade serous carcinoma.